BPG is committed to discovery and dissemination of knowledge
Articles in Press
8/28/2026 9:17:08 AM | Browse: 8 | Download: 0
Publication Name World Journal of Stem Cells
Manuscript ID 122513
DOI 10.4252/wjsc.122513
Country China
Category Cell & Tissue Engineering
Manuscript Type Review
Article Title Induced pluripotent stem cell-derived chimeric antigen receptor natural killer cells: Engineering innovations, translational hurdles and clinical prospects in immune therapy
Manuscript Source Unsolicited Manuscript
All Author List Xu-Lin Liu, Si-Min Han, Gang-Hui Ye, Qing-Lu Wang, Ying Luo and Yan-Mei Liu
Funding Agency and Grant Number
Funding Agency Grant Number
Zhejiang Medical Health Science & Technology Project 2022KY1403
Natural Scientific Foundation of Shandong Province ZR2025MS1369
Corresponding Author Ying Luo, MD, PhD, Department of Clinical Laboratory, Zibo Central Hospital, No. 54 Gongqingtuan West Road, Zhangdian District, Zibo 255000, Shandong Province, China. luoying1242@126.com
Key Words Induced pluripotent stem cells; Chimeric antigen receptor natural killer cells; Off-the-shelf immunotherapy; Cell engineering; Clinical translation; Tumor microenvironment; Genome editing; Synthetic biology
Core Tip Induced pluripotent stem cell-derived chimeric antigen receptor (CAR) natural killer cells provide a candidate standardized, cell-bank-driven platform for off-the-shelf immunotherapy. Their translational value should not be judged solely by CAR expression, enhanced cytotoxicity, or accumulated engineering modules. This review proposes a multilevel framework integrating product definition, effector execution, tissue delivery, host interaction, and translational implementation, and emphasizes dominant bottlenecks, evidence levels, engineering trade-offs, and the gap between preclinical functional enhancement and established clinical benefit.
Citation Liu XL, Han SM, Ye GH, Wang QL, Luo Y, Liu YM. Induced pluripotent stem cell-derived chimeric antigen receptor natural killer cells: Engineering innovations, translational hurdles and clinical prospects in immune therapy. World J Stem Cells 2026; In press
PDF 122513-in-press.pdf
Received
2026-04-22 05:59
Peer-Review Started
2026-04-22 05:59
First Decision by Editorial Office Director
Return for Revision
2026-06-23 03:15
Revised
2026-06-30 17:47
Publication Fee Transferred
Second Decision by Editor
2026-08-03 02:09
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director
2026-08-28 09:17
Articles in Press
2026-08-28 09:17
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 1948-0210 (online)
Open Access This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Copyright ©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com